LC-MS Analysis of Serum Lipidomic and Metabolomic Signatures in Pediatric Patients with Acute Lymphoblastic Leukemia

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2025 Mar 13

PMID 40075508

Authors

Feiyu Yan

Shengnan Wang

Yilin Wang

Yan Sun

Jing Yang

Lirong Sun

Yekaterina Y Zaytseva

Pan Deng

Lingzhen Wang

Affiliations

Soon will be listed here.

Abstract

Background: Acute lymphoblastic leukemia (ALL) is a prevalent hematologic malignancy that primarily affects children. The diagnosis and treatment of pediatric ALL remain challenging. This study aimed to identify differential lipids and metabolites that may hold potential for improving ALL treatment.

Methods: In this retrospective case-control study, serum samples obtained from children with ALL and healthy controls were analyzed. Serum lipidome and metabolome alterations of ALL were analyzed by comparing pediatric patients with ALL with healthy controls based on liquid chromatography high-resolution mass spectrometry analysis of serum lipidomic and metabolomic signatures.

Results: We identified 2,298 lipid features in the serum. Among them, 72 (3.13%) differed significantly in pediatric patients with ALL compared to healthy controls. Notably, sphingolipids (ceramide and sphingomyelin) and phospholipids exhibited the most pronounced changes. Targeted analysis of ceramides revealed significantly elevated levels of Cer 18:0 and Cer 20:0 in the serum of pediatric patients with ALL. Additionally, gut microbial-related lipids (such as sulfonolipids and fatty acid esters of hydroxy fatty acids) showed significant alterations. Metabolomic analysis identified 15 differential metabolites, indicating disrupted nucleotide and amino acid metabolism. Furthermore, the dysregulated lipids and metabolites correlated with various blood indicators, with ceramide and nucleosides positively associated with white blood cell count but negatively correlated with hemoglobin and platelet.

Conclusion: These findings shed light on abnormal molecular signatures contributing to pediatric ALL and may serve as potential biomarker panel for therapy of ALL.

References

Johnson E, Heaver S, Waters J, Kim B, Bretin A, Goodman A . Sphingolipids produced by gut bacteria enter host metabolic pathways impacting ceramide levels. Nat Commun. 2020; 11(1):2471. PMC: 7235224. DOI: 10.1038/s41467-020-16274-w. View

Deng P, Valentino T, Flythe M, Moseley H, Leachman J, Morris A . Untargeted Stable Isotope Probing of the Gut Microbiota Metabolome Using C-Labeled Dietary Fibers. J Proteome Res. 2021; 20(5):2904-2913. PMC: 8784920. DOI: 10.1021/acs.jproteome.1c00124. View

Vander Heiden M, DeBerardinis R . Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017; 168(4):657-669. PMC: 5329766. DOI: 10.1016/j.cell.2016.12.039. View

Brown E, Ke X, Hitchcock D, Jeanfavre S, Avila-Pacheco J, Nakata T . Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis and Symbiosis. Cell Host Microbe. 2019; 25(5):668-680.e7. PMC: 6544385. DOI: 10.1016/j.chom.2019.04.002. View

Li Y, Nicholson R, Summers S . Ceramide signaling in the gut. Mol Cell Endocrinol. 2022; 544:111554. PMC: 8828712. DOI: 10.1016/j.mce.2022.111554. View

Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu G . From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun. 2023; 14(1):3079. PMC: 10227015. DOI: 10.1038/s41467-023-38668-2. View

Hunger S, Raetz E . How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020; 136(16):1803-1812. DOI: 10.1182/blood.2019004043. View

Peppas I, Ford A, Furness C, Greaves M . Gut microbiome immaturity and childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2023; 23(8):565-576. PMC: 10243253. DOI: 10.1038/s41568-023-00584-4. View

Liebisch G, Fahy E, Aoki J, Dennis E, Durand T, Ejsing C . Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J Lipid Res. 2020; 61(12):1539-1555. PMC: 7707175. DOI: 10.1194/jlr.S120001025. View

10.

Ghaeidamini Harouni M, Rahgozar S, Rahimi Babasheikhali S, Safavi A, Ghodousi E . Fatty acid synthase, a novel poor prognostic factor for acute lymphoblastic leukemia which can be targeted by ginger extract. Sci Rep. 2020; 10(1):14072. PMC: 7442786. DOI: 10.1038/s41598-020-70839-9. View

11.

Saito T, Wei Y, Wen L, Srinivasan C, Wolthers B, Tsai C . Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository. Metabolomics. 2021; 17(7):64. PMC: 11446541. DOI: 10.1007/s11306-021-01814-2. View

12.

Toksvang L, Lee S, Yang J, Schmiegelow K . Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022; 36(7):1749-1758. PMC: 9252897. DOI: 10.1038/s41375-022-01591-4. View

13.

Inaba H, Mullighan C . Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539. PMC: 7604619. DOI: 10.3324/haematol.2020.247031. View

14.

Dany M, Gencer S, Nganga R, Thomas R, Oleinik N, Baron K . Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016; 128(15):1944-1958. PMC: 5064718. DOI: 10.1182/blood-2016-04-708750. View

15.

Liu H, Wu X, Dong Z, Luo Z, Zhao Z, Xu Y . Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production. J Lipid Res. 2013; 54(3):776-785. PMC: 3617951. DOI: 10.1194/jlr.M033811. View

16.

Deng P, Hoffman J, Petriello M, Wang C, Li X, Kraemer M . Dietary inulin decreases circulating ceramides by suppressing neutral sphingomyelinase expression and activity in mice. J Lipid Res. 2019; 61(1):45-53. PMC: 6939596. DOI: 10.1194/jlr.RA119000346. View

17.

Baran Y, Salas A, Senkal C, Gunduz U, Bielawski J, Obeid L . Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007; 282(15):10922-34. DOI: 10.1074/jbc.M610157200. View

18.

Liebisch G, Vizcaino J, Kofeler H, Trotzmuller M, Griffiths W, Schmitz G . Shorthand notation for lipid structures derived from mass spectrometry. J Lipid Res. 2013; 54(6):1523-1530. PMC: 3646453. DOI: 10.1194/jlr.M033506. View

19.

Chua L, Rajasuriar R, Lim Y, Woo Y, Loke P, Ariffin H . Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer. 2020; 20(1):151. PMC: 7041273. DOI: 10.1186/s12885-020-6654-5. View

20.

Sheridan M, Ogretmen B . The Role of Ceramide Metabolism and Signaling in the Regulation of Mitophagy and Cancer Therapy. Cancers (Basel). 2021; 13(10). PMC: 8161379. DOI: 10.3390/cancers13102475. View